Modulation of DC phenotype by the endothelin receptor antagonists
. | Human DCs, % . | hDCs + SA, % . | hDCs + SA + ABT-627, % . | hDCs + SA + A-192621, % . |
|---|---|---|---|---|
| CD1a | 39.19 ± 11.56 | 33.68 ± 12.30 | 37.40 ± 8.17 | 24.36 ± 16.48 |
| CD40 | 72.24 ± 4.75 | 87.25 ± 3.41* | 79.35 ± 5.49 | 92.04 ± 3.37 |
| CD80 | 34.29 ± 2.4 | 51.12 ± 1.69* | 45.50 ± 5.44 | 54.85 ± 2.44 |
| CD83 | 15.82 ± 0.52 | 34.71 ± 3.17* | 19.16 ± 1.31* | 48.18 ± 3.32* |
| CD86 | 69.09 ± 4.15 | 88.21 ± 1.86* | 78.46 ± 5.35 | 91.52 ± 2.21 |
| HLA-DR | 91.21 ± 0.77 | 96.15 ± 0.98* | 92.65 ± 2.29 | 96.23 ± 1.09 |
. | Human DCs, % . | hDCs + SA, % . | hDCs + SA + ABT-627, % . | hDCs + SA + A-192621, % . |
|---|---|---|---|---|
| CD1a | 39.19 ± 11.56 | 33.68 ± 12.30 | 37.40 ± 8.17 | 24.36 ± 16.48 |
| CD40 | 72.24 ± 4.75 | 87.25 ± 3.41* | 79.35 ± 5.49 | 92.04 ± 3.37 |
| CD80 | 34.29 ± 2.4 | 51.12 ± 1.69* | 45.50 ± 5.44 | 54.85 ± 2.44 |
| CD83 | 15.82 ± 0.52 | 34.71 ± 3.17* | 19.16 ± 1.31* | 48.18 ± 3.32* |
| CD86 | 69.09 ± 4.15 | 88.21 ± 1.86* | 78.46 ± 5.35 | 91.52 ± 2.21 |
| HLA-DR | 91.21 ± 0.77 | 96.15 ± 0.98* | 92.65 ± 2.29 | 96.23 ± 1.09 |
DCs indicates dendritic cells; hDCs, human dendritic cells; SA, staphylococcus aureus; ABT-627, endothelin receptor A antagonist; and A-192621, endothelin receptor B antagonist. Data are presented as means ± SEM.
Statistically significant difference. In the case of CD40, between human DCs and hDCs + SA(P = .012); CD80, between human DCs and hDCs + SA(P = .015); CD83, between human DCs and hDCs + SA (P = .003), between hDCs + SA and hDCs + SA + ABT-627 (P < .001), and between hDCs + SA and hDCs + SA + A-192621 (P = .014); CD86, between human DCs and hDCs + SA (P < .001); and HLA-DR, between human DCs and hDCs + SA (P = .004).